Mitotane’s mechanism of action

Mitotane (Mitotane) is a lipase inducer that mainly inhibits the synthesis and release of adrenocortical hormones by affecting the function of adrenocortical cells, thereby achieving the effect of treating adrenocortical cancer.

The mechanism of action mainly includes the following aspects:

1.Inhibition of the synthesis of adrenocortical hormones:Mitotane (mitotane) by inhibiting the chromogranin P450 system of mitochondria in adrenocortical cells, especially CYP11A1< The activities of /span> (cholesterol side chain cleavage enzyme) and CYP11B1 (11β-hydroxylase) interfere with the cholesterol metabolism pathway, thereby inhibiting the synthesis of adrenocortical hormones. This results in reduced levels of hormones such as cortisol, aldosterone, and androgens, which inhibit tumor growth and spread.

2.Induce apoptosis of adrenocortical cells:Mitotane (mitotane) may induce apoptosis of adrenocortical cancer cells by affecting the apoptosis pathway, thereby inhibiting tumor growth. Studies have shown that Mitotane can increase intracellular ROS levels, affect mitochondrial function, and induce cell apoptosis.

3.Influence on the function of adrenocortical cells:Mitotan (mitotane) may also inhibit the growth and spread of tumors by affecting the function of adrenocortical cells, such as reducing hormone secretion, changing the growth and differentiation status of cells, etc. This may involve the regulation of multiple signaling pathways, including the MAPK signaling pathway, PI3K/Akt signaling pathway, etc.

To sum up, Mitotane (mitotane) inhibits the growth and spread of adrenocortical cancer by inhibiting the synthesis of adrenocortical hormones, inducing apoptosis of adrenocortical cells and affecting the function of adrenocortical cells. Its mechanism of action is complex and involves the regulation of multiple signaling pathways and molecular mechanisms, providing a theoretical basis for its application in clinical treatment.